SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-22-000039
Filing Date
2022-06-17
Accepted
2022-06-17 16:16:42
Documents
13
Period of Report
2022-06-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20220615.htm   iXBRL 8-K 61912
2 EX-3.1 allo-20220617x8kxexhibit31.htm EX-3.1 10686
  Complete submission text file 0001737287-22-000039.txt   213398

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20220615.xsd EX-101.SCH 1987
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20220615_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20220615_pre.xml EX-101.PRE 12593
7 EXTRACTED XBRL INSTANCE DOCUMENT allo-20220615_htm.xml XML 10870
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 221024065
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences